Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Md Moazzem HossainDepartment of Biochemistry, Microbiology and Immunology, Wayne State University Medical School, Detroit, MI 48201.
Paul KingDepartment of Biochemistry, Microbiology and Immunology, Wayne State University Medical School, Detroit, MI 48201.
Justin HackettDepartment of Oncology, Wayne State University Medical School, Detroit, MI 48201.ORCID 0000-0002-3377-1499
Herve C GerardDepartment of Biochemistry, Microbiology and Immunology, Wayne State University Medical School, Detroit, MI 48201.
Rajmund NiwinskiDepartment of Biochemistry, Microbiology and Immunology, Wayne State University Medical School, Detroit, MI 48201.
Lan WuDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0001-6032-083X
Luc Van KaerDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0001-5275-2309
Gregory DysonDepartment of Oncology, Wayne State University Medical School, Detroit, MI 48201.
Heather GibsonDepartment of Biochemistry, Microbiology and Immunology, Wayne State University Medical School, Detroit, MI 48201.ORCID 0000-0003-2652-8252
Alexander D BorowskyDepartment of Pathology and Laboratory Medicine, Center for Comparative Medicine, University of California Davis, Davis, CA 95616.ORCID 0000-0003-3117-9202
Eric SebzdaDepartment of Biochemistry, Microbiology and Immunology, Wayne State University Medical School, Detroit, MI 48201.
Funding
Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancersU01CA196406 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOROWSKY, ALEXANDER D, ESSERMAN, LAURA J · 2015 to 2020
$5.8M
TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
A stable path for a core based scientist to advance imaging and cytometry in basic and preclinical research at the Karmanos Cancer InstituteR50CA251068 · NCI · WAYNE STATE UNIVERSITY · PI MOIN, KAMIAR · 2020 to 2024
$1.4M
American Cancer Society (ACS) DBG-23-103670-01-IBCDDOD | USA | MEDCOM | CDMRP | DOD Prostate Cancer Research Program (PCRP) PC140122Elsa U. Pardee Foundation (EUPF) N/ANCI NIH HHS P30 CA022453NCI NIH HHS R50 CA251068NCI NIH HHS T32 CA009531NCI NIH HHS U01 CA196406NIDDK NIH HHS P30 DK058404
6 · The paper itself
Abstract
Identifying tumor-mediated mechanisms that impair immunity is instrumental for the design of new cancer therapies. Regulatory T cells (Tregs) are a key component of cancer-derived immune suppression; however, these lymphocytes are necessary to prevent systemic autoimmunity in mice and humans, and thus, direct targeting of Tregs is not a clinical option for cancer patients. We have previously demonstrated that excising transcription factor Kruppel-like factor 2 (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner. · full record | OpenQuestion